Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Entrada Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
129
211
25.4
Research and development
21.1
35.9
66.6
99.9
125
142
General and administrative
5.57
15.2
30.6
32.3
38.5
41.1
Operating expenses
26.7
51.1
97.2
132
164
183
Operating income
-26.7
-51.1
-97.2
-3.16
47
-158
Other non-operating income
0.14
-0.03
2.63
15.2
19.5
15.1
Income tax
0
0
0
18.7
0.86
0.92
Net income
-26.5
-51.2
-94.6
-6.69
65.6
-144
EBITDA
-26.3
-50
-95.4
-0.32
50.8
-154
EPS, basic
-24.00
-8.16
-3.02
-0.20
1.76
-3.47
EPS, diluted
-24.00
-8.16
-3.02
-0.20
1.68
-3.47
Shares, basic (weighted)
1.11
6.27
31.3
33.1
37.3
41.4
Shares, diluted (weighted)
1.11
6.27
31.3
33.1
39
41.4
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
39
291
45.2
67.6
101
90.4
Short-term investments
0
Other current assets
0.9
7.64
21.2
11.9
16.4
8.72
Total current assets
39.9
299
210
370
440
306
Property, plant and equipment
3.04
6.26
7.68
11.2
10.9
7.31
Lease right-of-use assets
0
25.3
81.5
71.1
60.5
Other non-current assets
0.54
0.87
5.21
2.79
0.28
0.07
Total assets
43.5
306
252
469
526
377
Accounts payable
1.6
0.71
5.99
3.28
4.26
2.29
Accrued liabilities
1.76
6.01
7.58
11.3
13.3
17.7
Deferred revenue
0
132
13.7
0.34
Total current liabilities
3.36
6.72
22
159
39.5
24.5
Lease liabilities
0
17.5
60.3
51.6
46.8
Total liabilities
3.36
7.12
39.5
227
97.6
71.2
Paid-in capital
1.02
392
403
437
558
579
Retained earnings
-42.5
-93.7
-188
-195
-129
-273
Other comprehensive income
0
-2.06
0.2
-0.04
0.65
Shareholders' equity
-41.5
299
213
242
429
306
Total equity
-41.5
299
213
242
429
306
Total liabilities and equity
43.5
306
252
469
526
377
Shares outstanding
1.24
31.2
31.4
33.4
37.6
38.3
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-26.5
-51.2
-94.6
-6.69
65.6
-144
Depreciation and amortization
0.33
1.12
1.9
2.84
3.77
4.1
Stock-based compensation
0.33
2.53
9.9
13.1
17.9
19.6
Deferred income tax
0
0
0
0
Cash from operations
-25.6
-50.9
-93.8
140
-41.6
-129
Capital expenditures
-2.32
-4.58
-2.89
-5.61
-3.16
-1.04
Purchases of investments
0
-222
-407
-438
-142
Sales and maturities of investments
0
76.2
274
413
259
Cash from investing
-2.32
-4.58
-149
-138
-27.8
117
Stock issued
0.21
0.41
0.28
0.44
2.78
0.43
Cash from financing
50.1
307
0.48
21
103
0.89
Net change in cash
22.2
252
-242
22.4
33.6
-10.8
Free cash flow
-27.9
-55.4
-96.7
134
-44.7
-130
Income taxes paid
0
14.7
4.62
1.7
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.16 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-3,767.0%
Operating income / revenue.
EBITDA margin
-3,688.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-3,538.0%
Net income / revenue.
FCF margin
-2,867.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-2,874.0%
Cash from operations / revenue.
Return on equity (ROE)
-71.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-55.5%
Net income / average total assets.
Return on invested capital (ROIC)
-104.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
3,003.0%
Research and development expense / revenue.
Stock-based pay / revenue
413.3%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
6.9%
Capital expenditures / revenue.
D&A / revenue
78.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-87.9%
Revenue vs the same period a year earlier. Only from a positive base.
Operating income growth, 1y
-435.9%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
-402.9%
EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
-319.0%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
-306.5%
EPS vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-28.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
12.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-28.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
14.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
54.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
6.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
9.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
106.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
10.9x
Current assets / current liabilities.
Quick ratio
4.65x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.65x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.11
Revenue / diluted weighted shares.
FCF per share
-$3.18
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.19
Cash from operations / diluted weighted shares.
Book value per share
$5.99
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
51.2x
Market cap / revenue.
P/B
1.03x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.03x
Market cap / tangible book value, when positive.
EV/Sales
30.0x
Enterprise value / revenue.
FCF yield
-56.0%
Free cash flow / market cap.
Earnings yield
-69.1%
Net income / market cap (the inverse of P/E).
What was Entrada Therapeutics, Inc.'s revenue in fiscal 2025?
Entrada Therapeutics, Inc. reported revenue of $25.4M for fiscal 2025, 87.9% lower than the year before.
Was Entrada Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $143.8M.
How much free cash flow did Entrada Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $128.5M minus capital expenditures of $1.0M left free cash flow of -$129.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.